Introducing vedolizumab to clinical practice: who, when, and how?
about
Optimal delivery of follow-up care after surgery for Crohn's disease: current perspectivesCrohn's disease: a clinical updateSystematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.Use of Piezoelectric Immunosensors for Detection of Interferon-Gamma Interaction with Specific Antibodies in the Presence of Released-Active Forms of Antibodies to Interferon-GammaVedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.New choices, new challenges: Anti-TNF versus anti-integrin molecule therapy in IBD.New pharmaceuticals in inflammatory bowel diseaseEfficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort.Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.Biologic agents for IBD: practical insights.Update on the Medical Management of Crohn's Disease.Therapeutic innovations in inflammatory bowel diseases.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease.Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis.Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?Serology of Viral Infections and Tuberculosis Screening in an IBD Population Referred to a Tertiary Centre of Southern ItalyTHE APPROVAL OF VEDOLIZUMAB FOR THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES IN BRAZIL: the beginning of a new biological era.Biosimilar and innovator anti-Tumour Necrosis Factor (TNF) or lymphocyte trafficking blockade: Which one to select?Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.
P2860
Q26740356-607238EF-12AA-44F2-AAD2-46564F6F63D5Q26777696-CBF1111A-0FB2-49A5-89ED-75416E9C0CEAQ30234628-05B13755-C7E7-4D72-B5D8-788EAFB2FA96Q30391107-AA895E92-07AC-4D03-BD7B-779CD00F4FD7Q33607108-7A1C13DF-ED43-412F-8F73-292D0D20F295Q35962448-908CB463-F4BB-460A-BCD0-F011A4C071CBQ36243912-5412A3CD-C21E-48DC-BAB8-09CE659F4C44Q36557868-C3B7FE7F-1966-4A4A-B459-B2E878490D4BQ37098441-19A3407E-547D-468B-BF29-C90D8752018DQ38542151-9E28DF52-0F68-4812-9108-12B55A487271Q38568898-7F487502-0EE4-4380-BB0C-C04E85BDBAB0Q38585634-037C0874-3B67-4C94-BB27-657BF99C8FEBQ38618178-1492AAA1-1CE8-4DA1-AC9B-6DD8CB8B98B1Q38822920-8D3661EF-E6F9-42B3-A390-E4A8A7CC00FAQ38974524-79E19B19-8C15-499D-B4BB-C1173504FB39Q39147818-CE1FB4B4-559E-4383-9D63-BE38808B6A6DQ42695266-5E3E34F2-3C34-48A6-AB7D-D65DD4B4F72CQ42718254-032CE14E-B2E8-42A1-9F29-1770412D3BC6Q51713787-2B17777B-C079-4800-BED3-7AFC0B52C683Q51715018-0F2B35B7-F091-4851-AA52-0B1ED26569E6Q54530445-6FB0E503-D73E-43B4-894F-6F943B863AD6
P2860
Introducing vedolizumab to clinical practice: who, when, and how?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Introducing vedolizumab to clinical practice: who, when, and how?
@ast
Introducing vedolizumab to clinical practice: who, when, and how?
@en
type
label
Introducing vedolizumab to clinical practice: who, when, and how?
@ast
Introducing vedolizumab to clinical practice: who, when, and how?
@en
prefLabel
Introducing vedolizumab to clinical practice: who, when, and how?
@ast
Introducing vedolizumab to clinical practice: who, when, and how?
@en
P2860
P356
P1476
Introducing vedolizumab to clinical practice: who, when, and how?
@en
P2093
R V Bryant
S P L Travis
P2860
P304
P356
10.1093/ECCO-JCC/JJV033
P577
2015-02-16T00:00:00Z